Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China.
J Hematol Oncol. 2019 Feb 8;12(1):15. doi: 10.1186/s13045-019-0703-z.
The relapse rate remains high after chemotherapy for adult patients with acute lymphoblastic leukemia (ALL). With better molecular diagnosis and classification as well as better assessment for minimal residual disease, major progress in the treatment for refractory and/or relapsed ALL is being made. In addition to the tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome-positive ALL, immunotherapeutic agents, blinatumomab, inotuzumab ozogamicin (INO), and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being incorporated into induction chemotherapy regimens and combined with TKIs for ALL therapy. A novel low-intensity regimen, miniHCVD-INO-blinatumomab, appears to be less toxic and more effective than conventional intensive chemotherapy regimens. This review summarized new therapeutic researches of ALL and updated latest progress in clinical trials on bispecific antibodies, antibody-drug conjugates, and new regimens incorporating these novel antibodies.
急性淋巴细胞白血病（ALL）成人患者经化疗后复发率仍较高。随着更好的分子诊断和分类以及对微小残留病的更好评估，难治性和/或复发 ALL 的治疗取得了重大进展。除了费城染色体阳性 ALL 的酪氨酸激酶抑制剂（TKI）外，免疫治疗药物blinatumomab、inotuzumab ozogamicin（INO）和嵌合抗原受体（CAR）T 细胞正在改变 ALL 的治疗模式。Blinatumomab 和 INO 被纳入诱导化疗方案，并与 ALL 治疗中的 TKI 联合使用。一种新型低强度方案 miniHCVD-INO-blinatumomab 似乎比传统强化化疗方案毒性更小、更有效。本文总结了 ALL 的新治疗研究，并更新了双特异性抗体、抗体药物偶联物以及包含这些新型抗体的新方案的临床试验的最新进展。
